Imidazole derivatives used as TAFIa inhibitors

US8710232B2 · kind B2 · utility

Assignee

• Sanofi-Aventis Deutschland GMBH · DE

Inventors

• Christopher Kallus · Frankfurt am Main, DE
• Holger Heitsch · Hofheim, DE
• Andreas Lindenschmidt · Bad Soden, DE
• Sven Grueneberg · Kelkheim, DE
• Hauke Szillat · Frankfurt, DE

Key dates

• Filing date: Oct 23, 2006
• Grant date: Apr 29, 2014
• Expiry date: Nov 10, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/06
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds of formula (I)which are inhibitors of the activated thrombin-activatable fibrinolysis inhibitor. The compounds of formula (I) are suited for producing medicaments for the prevention and treatment of diseases accompanied by thromboses, embolisms, hypercoagulability or fibrotic changes.